Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% year on year to $204.1 million. The company expects the full year’s revenue to be around $824 million, close to analysts’ estimates. Its non-GAAP profit of $0.54 per share was 20.4% above analysts’ consensus estimates.
Is now the time to buy Repligen? Find out by accessing our full research report, it’s free.
Repligen (RGEN) Q2 CY2026 Highlights:
- Revenue: $204.1 million vs analyst estimates of $201.8 million (11.9% year-on-year growth, 1.1% beat)
- Adjusted EPS: $0.54 vs analyst estimates of $0.45 (20.4% beat)
- Adjusted EBITDA: $43.77 million vs analyst estimates of $38.3 million (21.4% margin, 14.3% beat)
- The company slightly lifted its revenue guidance for the full year to $824 million at the midpoint from $818 million
- Management raised its full-year Adjusted EPS guidance to $2.06 at the midpoint, a 2.5% increase
- Operating Margin: 6.8%, in line with the same quarter last year
- Free Cash Flow Margin: 13%, up from 11.8% in the same quarter last year
- Organic Revenue rose 13% year on year (beat)
- Market Capitalization: $7.40 billion
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We were very pleased to deliver 13% organic growth in the second quarter, reflecting sequential acceleration and continued market outperformance. This reflects the strength and diversification of our portfolio and our disciplined execution. The order momentum from the first quarter continued into the second quarter. Our strong first half results and improved line of sight to the second half give us the confidence to increase our full year guidance.”
Company Overview
With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ:RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Luckily, Repligen’s sales grew at a decent 9.1% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Repligen’s annualized revenue growth of 12.5% over the last two years is above its five-year trend, suggesting its demand recently accelerated. 
We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Repligen’s organic revenue averaged 12.1% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. 
This quarter, Repligen reported year-on-year revenue growth of 11.9%, and its $204.1 million of revenue exceeded Wall Street’s estimates by 1.1%.
Looking ahead, sell-side analysts expect revenue to grow 11.7% over the next 12 months, similar to its two-year rate. This projection is commendable and suggests the market sees success for its products and services.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Repligen has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 19.1%.
Looking at the trend in its profitability, Repligen’s adjusted operating margin decreased by 16.2 percentage points over the last five years, but it rose by 4.2 percentage points on a two-year basis. Still, shareholders will want to see Repligen become more profitable in the future.
In Q2, Repligen generated an adjusted operating margin profit margin of 16.7%, up 4.6 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Sadly for Repligen, its EPS declined by 3.8% annually over the last five years while its revenue grew by 9.1%. This tells us the company became less profitable on a per-share basis as it expanded.
We can take a deeper look into Repligen’s earnings to better understand the drivers of its performance. As we mentioned earlier, Repligen’s adjusted operating margin expanded this quarter but declined by 16.2 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Repligen reported adjusted EPS of $0.54, up from $0.37 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Repligen’s full-year EPS to grow 14.2% from $1.97 to $2.25.
Key Takeaways from Repligen’s Q2 Results
It was good to see Repligen beat analysts’ EPS expectations this quarter. We were also glad its organic revenue outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 4.2% to $136.50 immediately following the results.
Repligen had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).